Eton Pharmaceuticals (ETON) reported Q1 non-GAAP earnings Tuesday of $0.07 per diluted share, compared with breakeven EPS a year earlier.
One analyst polled by FactSet expected a loss of $0.01.
Net revenue for the quarter ended March 31 was $17.3 million, up from $8 million a year earlier.
Three analysts surveyed by FactSet expected $15.1 million.
The company said that as of March 31, it had cash and cash equivalents of $17.4 million.
Eton shares were rising 2.8% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.